Eli Lilly will speak with regulators about the Phase III data. Image credit: luchschenF / Shutterstock.com Eli Lilly’s oral targeted cancer therapy, Retevmo, has shown benefit as an adjunctive therapy ...

Roche will now share data from the Phase III MAJESTY study in membranous nephropathy with regulators. Image credit: Peakstock via ShutterStock.com. Roche is heading to regulators after its blockbuster ...

Knee osteoarthritis continues to be a major source of pain and reduced mobility. Credit: SORASIT SRIKHAM-ON / Shutterstock.com. MEDIPOST has submitted an investigational new drug (IND) amendment to ...

The vaccine aims for broad protection against seasonal, future, and pandemic influenza strains. Credit: Sergii Sobolevskyi / Shutterstock.com. Centivax has commenced participant dosing in its Phase Ia ...

This comes as Upstream Bio's twice-yearly dose of verekitug fails to match Tezspire’s efficacy in reducing severe asthma exacerbations.

Senti Biosciences presented data at ASH Annual Meeting showing SENTI-202 achieved durable remissions in r/r AML. Credit: Ekahardiwito / Shutterstock.com. Senti Biosciences has completed enrolment of ...

Nektar will now take Treg therapy, rezpeg to a Phase III trial in atopic dermatitis (AD), which is set to begin in Q2 2026.

Clinical trials are facing new and evolving challenges as costs increase and approval timelines remain lengthy. Modernisation ...

Evommune’s potential Dupixent competitor has met its primary endpoint in a Phase IIa atopic dermatitis (AD) trial, achieving a 33% reduction in Eczema Area and Severity Index (EASI).

As the oral weight loss drug market has started to emerge, AstraZeneca has told shareholders that it will advance its ...

Participants were randomised into 2:1 ratio to receive either BRTX-100 or placebo through a minimally invasive outpatient intradiscal procedure. Credit: create jobs 51 / Shutterstock.com.